HOW TO PRESCRIBE

HOW TO PRESCRIBE

What to know to prescribe XPHOZAH 30 mg BID

Not available in retail pharmacies

XPHOZAH prescriptions cannot be filled through a traditional retail pharmacy

How to prescribe through ArdelyxAssist

Send XPHOZAH prescriptions to Transition Pharmacy Services in Trevose, Pennsylvania, the ArdelyxAssist™ partner pharmacy
Computer icon
E-prescribe an Rx
Transition Pharmacy Services, LLC
Trevose, PA 19053
NPI #: 1336325265
Phone call icon
Call in an Rx
877-527-3927 Option 1
Fax icon
Fax in an Rx
877-594-4906
Use your own Rx or our prescription form
How to prescribe through specialty pharmacy network

Alternatively, if you have an established relationship and prefer, you can send XPHOZAH prescriptions directly to a specialty pharmacy in our network

List of Network Specialty Pharmacies

RELATED LINKS

Access Support

Indication

XPHOZAH (tenapanor) 30 mg BID is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Important Safety Information

Contraindications

XPHOZAH is contraindicated in:

  • Pediatric patients under 6 years of age
  • Patients with known or suspected mechanical gastrointestinal obstruction

Warnings and precautions

Diarrhea

Patients may experience severe diarrhea. Treatment with XPHOZAH should be discontinued in patients who develop severe diarrhea.

Most Common Adverse Reactions

Diarrhea, which occurred in 43-53% of patients, was the only adverse reaction reported in at least 5% of XPHOZAH-treated patients with CKD on dialysis across trials. The majority of diarrhea events in XPHOZAH-treated patients were reported to be mild-to-moderate in severity and resolved over time, or with dose reduction. Diarrhea was typically reported soon after initiation but could occur at any time during treatment with XPHOZAH. Severe diarrhea was reported in 5% of XPHOZAH-treated patients in these trials.

For additional safety information, please see full Prescribing Information.

Indication

XPHOZAH (tenapanor) 30 mg BID is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Important Safety Information

Contraindications

XPHOZAH is contraindicated in:

  • Pediatric patients under 6 years of age
  • Patients with known or suspected mechanical gastrointestinal obstruction

Warnings and precautions

Diarrhea

Patients may experience severe diarrhea. Treatment with XPHOZAH should be discontinued in patients who develop severe diarrhea.

Most Common Adverse Reactions

Diarrhea, which occurred in 43-53% of patients, was the only adverse reaction reported in at least 5% of XPHOZAH-treated patients with CKD on dialysis across trials. The majority of diarrhea events in XPHOZAH-treated patients were reported to be mild-to-moderate in severity and resolved over time, or with dose reduction. Diarrhea was typically reported soon after initiation but could occur at any time during treatment with XPHOZAH. Severe diarrhea was reported in 5% of XPHOZAH-treated patients in these trials.

For additional safety information, please see full Prescribing Information.

Close

Connect with us for more information and continued updates about XPHOZAH.

Fill out the information below to register for updates.

*Required field.

Close

Close